This article is more than 5 years old. Information may no longer be current.

Alphagan P to launch by September

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Alphagan P (brimonidine tartrate ophthalmic solution, Allergan) 0.15% will be on pharmacy shelves by September, according to Allergan managers.

Alphagan P, a lower dose formulation of company's glaucoma drug Alphagan, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.

Reports on the formulation also indicate Alphagan P contains a different preservative to control some of the side effects that occurred with Alphagan. In two 12-month clinical trials, the difference in IOP reduction between the two agents was less than or equal to 1 mm Hg at all time points at all scheduled visits.

By changing the preservative from benzalkonium chloride to Purite (the preservative used in Allergan's Refresh Tears Lubricant Eye Drops), side effects such as allergic conjunctivitis and ocular pruritus should be reduced, according to Allergan officials.